Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing

Inclusion Criteria: * Signed and dated written informed consent * Male or female newly diagnosed multiple myeloma (NDMM) patients 18 to 70 years old on the day of signing informed consent who had ASCT with post-ASCT response of partial response (PR) or better as defined by International Myeloma Working Group (IMWG). The induction regimen should include a proteasome inhibitors (PI), immunomodulatory drugs (IMiD) and anti-CD38 monoclonal antibody * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Patients with high-risk and international staging system (ISS) stage-III disease in 15% of the intent to treat population. Patients with 1q gain, 1p deletion, del17p, t\[4;14\], or t\[14;16\] by fluorescence in situ hybridization \[FISH\] will be categorized as having high risk disease * Absolute neutrophil count, ≥ 1.0 × 10\^9/L * Platelets ≥ 75,000/μL * Hemoglobin level ≥ 7.5 g/dL * Total bilirubin \< 1.5 times institutional upper limit of normal (ULN) (if patient has known history of Gilbert's syndrome, total bilirubin will not be used as an exclusion criteria) * Corrected serum calcium, ≤ 14.0 mg/dL (≤ 3.5 mmol/L) * Platelet count, ≥ 50 × 10\^9/L (≥ 50 × 10\^9/L if ≥ 50% of the bone marrow was infiltrated with multiple myeloma \[MM\] cells) * Alanine aminotransferase and aspartate aminotransferase levels \< 2.5 times the upper limit of normal * Creatinine clearance ≥ 30 mL/min (per institutional standard) * All ASCT-related toxicities must have recovered to…